phrykt

Immunovant, Inc. (IMVT): who owns it and who trades it

As of Nov 16, 2026, IMVT insiders reported 63 open-market sales worth $16.6M and 1 purchase worth $350M in the last 12 months, with 9% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew J. Fromkin (Director), with $8M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Immunovant

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IMVT

226 funds and institutions reported IMVT shares worth $4.4B at the end of Q2 2026, about 56% of the company. The largest holder is FMR LLC (Fidelity) with 7.9%.

Funds and institutions (13F) 56%Everyone else 44%

10 largest owners, by share of the company

FMR LLC (Fidelity)7.9%
Deep Track Capital, LP4.5%
BlackRock, Inc.3.5%
Farallon Capital Management, L.l.c.2.8%
Baker Bros. Advisors LP2.6%
State Street Corp2.2%
Morgan Stanley2.2%
TCG Crossover Management, LLC2.2%
Vanguard Portfolio Management LLC1.9%
Vanguard Capital Management LLC1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)16.19M7.88%$624M-4%
Deep Track Capital, LP9.34M4.55%$360M-19%
BlackRock, Inc.7.18M3.50%$277M+9%
Farallon Capital Management, L.l.c.5.80M2.83%$224M+275%
Baker Bros. Advisors LP5.44M2.65%$209M-0%
State Street Corp4.62M2.25%$178M+2%
Morgan Stanley4.53M2.21%$175M+17%
TCG Crossover Management, LLC4.46M2.17%$172MNo change
Vanguard Portfolio Management LLC3.91M1.90%$151M+6%
Vanguard Capital Management LLC3.64M1.77%$140M+1%
California State Teachers Retirement System3.53M1.72%$91.7M+3647%
Jennison Associates LLC3.31M1.61%$128M+4%
Rtw Investments, LP3.18M1.55%$122MNo change
Two Seas Capital LP3.15M1.53%$121M-2%
ADAR1 Capital Management, LLC2.33M1.14%$89.8M-13%
Geode Capital Management, LLC2.23M1.09%$86.1M+7%
T. Rowe Price Investment Management, Inc.2.22M1.08%$85.6M-38%
Woodline Partners LP1.98M0.96%$76.1MNo change
T. Rowe Price Associates1.83M0.89%$70.5M+439%
Goldman Sachs Group Inc1.75M0.85%$67.5M-2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IMVT insiders reported $350M of open-market purchases and $16.6M of sales. 9% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$350M
1 trades, 1 people
Sales, 12 months
$16.6M
63 trades, 9 people
Sales under a 10b5-1 plan
9%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 12, 2026

Purchases and sales by month

$350M$350MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Atul PandeDirectorSale plan3,000$36.00$108KForm 4
Oct 28, 2026Tiago GiraoCFOSale6,606$28.50$188KForm 4
Oct 21, 2026Jay S StoutChief Technology OfficerSale2,595$28.94$75.1KForm 4
Oct 7, 2026Melanie GloriaChief Operating OfficerSale2,241$32.06$71.8KForm 4
Oct 7, 2026Jay S StoutChief Technology OfficerSale2,213$32.06$70.9KForm 4
Oct 7, 2026Jay S StoutChief Technology OfficerSale1,596$32.06$51.2KForm 4
Oct 7, 2026Tuyl Christopher VanChief Legal OfficerSale1,327$32.06$42.5KForm 4
Oct 2, 2026Eric VenkerCEOSale3,506$34.11$120KForm 4
Sep 23, 2026Tuyl Christopher VanChief Legal OfficerSale2,846$36.36$103KForm 4
Aug 28, 2026Atul PandeDirectorSale plan1,500$43.27$64.9KForm 4
Aug 20, 2026Melanie GloriaChief Operating OfficerSale3,056$44.16$135KForm 4
Jul 24, 2026Atul PandeDirectorSale plan1,500$39.80$59.7KForm 4
Jul 23, 2026Tiago GiraoCFOSale6,798$38.69$263KForm 4
Jul 23, 2026Jay S StoutChief Technology OfficerSale2,857$38.69$111KForm 4
Jul 8, 2026Melanie GloriaChief Operating OfficerSale106$39.99$4.2KForm 4
Jul 8, 2026Melanie GloriaChief Operating OfficerSale1,930$39.53$76.3KForm 4
Jul 8, 2026Tuyl Christopher VanChief Legal OfficerSale63$39.99$2.5KForm 4
Jul 8, 2026Tuyl Christopher VanChief Legal OfficerSale1,143$39.53$45.2KForm 4
Jul 8, 2026Jay S StoutChief Technology OfficerSale1,399$39.53$55.3KForm 4
Jul 8, 2026Jay S StoutChief Technology OfficerSale77$39.99$3.1KForm 4
Jul 8, 2026Jay S StoutChief Technology OfficerSale105$39.99$4.2KForm 4
Jul 8, 2026Jay S StoutChief Technology OfficerSale1,906$39.53$75.3KForm 4
Jul 2, 2026Eric VenkerCEOSale3,092$38.48$119KForm 4
Jun 26, 2026Melanie GloriaChief Operating OfficerSale14,748$38.18$563KForm 4
Jun 26, 2026Melanie GloriaChief Operating OfficerSale2,966$38.95$116KForm 4
Jun 26, 2026Jay S StoutChief Technology OfficerSale6,723$38.94$262KForm 4
Jun 26, 2026Jay S StoutChief Technology OfficerSale33,277$38.18$1.3MForm 4
Jun 26, 2026Tuyl Christopher VanChief Legal OfficerSale2,842$38.96$111KForm 4
Jun 26, 2026Tuyl Christopher VanChief Legal OfficerSale14,982$38.19$572KForm 4
Jun 26, 2026Tiago GiraoCFOSale10,000$38.46$385KForm 4
Jun 26, 2026Atul PandeDirectorSale plan1,500$38.01$57KForm 4
Jun 18, 2026Tuyl Christopher VanChief Legal OfficerSale2,634$35.39$93.2KForm 4
Jun 15, 2026Atul PandeDirectorSale plan1,500$34.02$51KForm 4
May 28, 2026Andrew J. FromkinDirectorSale210,468$33.56$7.1MForm 4
May 28, 2026Andrew J. FromkinDirectorSale11,483$32.64$375KForm 4
May 20, 2026Melanie GloriaChief Operating OfficerSale249$30.41$7.6KForm 4
May 20, 2026Melanie GloriaChief Operating OfficerSale1,698$32.95$55.9KForm 4
May 20, 2026Melanie GloriaChief Operating OfficerSale1,168$32.15$37.6KForm 4
May 20, 2026Atul PandeDirectorSale plan6,000$32.00$192KForm 4
May 1, 2026Robert Graham SusmanDirectorSale plan2,502$27.17$68KForm 4
Apr 23, 2026Tiago GiraoCFOSale25,760$29.62$763KForm 4
Apr 23, 2026Jay S StoutChief Technology OfficerSale2,754$29.62$81.6KForm 4
Apr 8, 2026Tuyl Christopher VanChief Legal OfficerSale5,165$24.83$128KForm 4
Apr 8, 2026Melanie GloriaChief Operating OfficerSale8,722$24.83$217KForm 4
Apr 8, 2026Jay S StoutChief Technology OfficerSale8,614$24.83$214KForm 4
Apr 8, 2026Jay S StoutChief Technology OfficerSale1,518$24.83$37.7KForm 4
Apr 2, 2026Eric VenkerCEOSale1,409$24.60$34.7KForm 4
Apr 2, 2026Eric VenkerCEOSale12,820$24.04$308KForm 4
Mar 18, 2026Tuyl Christopher VanChief Legal OfficerSale2,877$24.97$71.8KForm 4
Feb 25, 2026Melanie GloriaChief Operating OfficerSale942$28.90$27.2KForm 4
Feb 25, 2026Melanie GloriaChief Operating OfficerSale859$28.16$24.2KForm 4
Feb 25, 2026Melanie GloriaChief Operating OfficerSale1,437$26.98$38.8KForm 4
Jan 21, 2026Jay S StoutChief Technology OfficerSale1,977$26.03$51.5KForm 4
Jan 7, 2026Jay S StoutChief Technology OfficerSale1,148$26.51$30.4KForm 4
Jan 7, 2026Jay S StoutChief Technology OfficerSale55$26.92$1.5KForm 4
Dec 18, 2025Tuyl Christopher VanChief Legal OfficerSale2,284$27.38$62.5KForm 4
Dec 18, 2025Tuyl Christopher VanChief Legal OfficerSale8,529$26.78$228KForm 4
Dec 12, 2025Roivant Sciences Ltd.DirectorPurchase16.67M$21.00$350MForm 4
Dec 1, 2025Andrew J. FromkinDirectorSale plan19,351$23.14$448KForm 4
Dec 1, 2025Andrew J. FromkinDirectorSale plan2,898$23.95$69.4KForm 4
Dec 1, 2025Douglas J. HughesDirectorSale plan13,091$23.14$303KForm 4
Dec 1, 2025Douglas J. HughesDirectorSale plan1,909$23.96$45.7KForm 4
Nov 20, 2025Melanie GloriaChief Operating OfficerSale10,251$23.54$241KForm 4
Nov 20, 2025Melanie GloriaChief Operating OfficerSale2,375$23.97$56.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Roivant Sciences Ltd.Director, 10% owner$350M–Dec 12, 2025
Andrew J. FromkinDirector–$8MMay 28, 2026
Jay S StoutChief Technology Officer–$2.4MOct 21, 2026
Melanie GloriaChief Operating Officer–$1.7MOct 7, 2026
Tiago GiraoChief Financial Officer–$1.6MOct 28, 2026
Tuyl Christopher VanChief Legal Officer–$1.5MOct 7, 2026
Eric VenkerChief Executive Officer, Director–$581KOct 2, 2026
Atul PandeDirector–$533KNov 11, 2026
Douglas J. HughesDirector–$349KDec 1, 2025
Robert Graham SusmanDirector–$68KMay 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMVT short interest

Moderate short interest. 9.0% of IMVT shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 18.55M IMVT shares were sold short, 9.0% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 15.3 trading days (days to cover).

Shares short, % of all shares

8.98%May 15Oct 3010.3%

Days to cover

15.3May 15Oct 3020.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202618.55M8.98%+2%1.22M15.3
Oct 15, 202618.27M8.85%+5%1.48M12.3
Sep 30, 202617.42M8.43%+1%1.81M9.6
Sep 15, 202617.25M8.35%+9%1.20M14.3
Aug 31, 202615.78M7.64%-7%1.12M14.1
Aug 14, 202616.98M8.22%+4%1.13M15.1
Jul 31, 202616.38M7.98%-8%884,26618.5
Jul 15, 202617.76M8.65%-1%1.06M16.7
Jun 30, 202617.99M8.76%-7%2.09M8.6
Jun 15, 202619.34M9.42%+1%1.37M14.1
May 29, 202619.21M9.36%-6%3.85M5.0
May 15, 202620.37M9.92%+10%1.24M16.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Immunovant company events

Immunovant filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Sep 3, 2026VoteReported shareholder vote results. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. May 20, 2026ResultsReleased financial results. Filing
  5. Feb 6, 2026ResultsReleased financial results. Filing
  6. Dec 12, 2025AnnouncementImmunovant, Inc. entered into an underwriting agreement with Leerink Partners LLC, relating to the issuance and sale in an underwritten offering by the Company of 26.2 million shares of the Company’s common stock, par value $0.0001 per share, at an offering price of $21.00 per share. Filing
  7. Dec 11, 2025AnnouncementImmunovant, Inc. announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to the Company of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by the Company in connection with the transaction. Filing
  8. Nov 21, 2025LeadershipMichael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc., effective November 21, 2025, in connection with the Company’s restructuring of its R&D leadership structure under the Company’s Chief Executive Officer, Eric Venker, M.D., PharmD. The Company has entered… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Immunovant financials

Famous investors that hold IMVT

4 of the 50 well-known investors we track reported holding IMVT in their latest 13F filing. The largest position is Jim Simons's, worth $26.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026779,500$26.3M0.0%+7%
Ken Fisher · Fisher Asset ManagementQ3 2026545,730$18.4M0.0%New
Israel Englander · Millennium ManagementQ3 2026256,789$8.7M0.0%-22%
David Einhorn · Greenlight Capital (DME)Q3 202670,140$2.4M0.1%-25%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Immunovant, Inc. (IMVT) stock

Who owns the most IMVT stock?

The largest reported owner of Immunovant, Inc. (IMVT) is FMR LLC (Fidelity), with 7.9% of the company. In total, 226 funds and institutions reported holding IMVT at the end of Q2 2026, together about 56% of the shares. See the largest owners.

Are IMVT insiders buying or selling?

In the last 12 months, IMVT insiders reported 1 open-market purchase worth $350M and 63 sales worth $16.6M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in IMVT?

As of Oct 30, 2026, 18.55M IMVT shares were sold short, 9.0% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 15.3 trading days (days to cover). See the history.

Which famous investors hold IMVT?

4 of the 50 well-known investors we track reported IMVT in their latest 13F filing, including Jim Simons, Ken Fisher, Israel Englander. The largest position is worth $26.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.